封面
市场调查报告书
商品编码
1547105

尿路表皮癌症诊断市场:全球产业分析,规模,占有率,成长,趋势,预测,2024年~2033年

Urothelial Carcinoma Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日期: | 出版商: Persistence Market Research | 英文 245 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research最近发布了一份关于全球尿路上皮癌诊断市场的综合报告。该报告全面评估了主要市场动态,包括推动因素、趋势、机会和挑战,并提供了有关市场结构的详细见解。

主要的洞察

  • 尿路上皮癌诊断市场规模(2024 年):18.086 亿美元
  • 市场预测金额(2033 年):43.672 亿美元
  • 全球市场成长率(2024-2033 年复合年增长率):10.3%

尿路上皮癌诊断市场 - 报告范围:

尿路上皮癌诊断包括用于检测和监测尿路上皮癌的各种技术和工具,尿路上皮癌是一种发生在膀胱和泌尿系统其他部位的癌症。这些诊断包括影像技术、生物标记测试和分子诊断。该市场服务于各种医疗保健机构,包括医院、诊断实验室和肿瘤中心。尿路上皮癌发生率的上升、诊断技术的进步以及人们对癌症早期检测的认识不断增强,推动了市场的成长。

推动市场成长的因素:

全球尿路上皮癌诊断市场受到几个关键因素的推动,例如尿路上皮癌盛行率的增加以及易患此类癌症的老年人口的增加。诊断技术的进步,例如新一代定序和液体活检的发展,可以更准确地早期检测癌症并改善治疗结果。此外,个人化医疗和标靶治疗的日益普及也推动了对先进诊断解决方案的需求。医疗保健支出的增加和医疗基础设施的改善也有助于市场扩张。

市场阻碍因素:

儘管预期成长前景良好,但尿路上皮癌诊断市场面临着诊断成本高和低收入地区先进诊断技术取得有限等挑战。诊断程序的复杂性和对专业设备的需求可能会成为市场成长的障碍,特别是在医疗保健预算有限的新兴市场。此外,监管障碍和研发方面的大量投资需求可能会影响新技术推向市场的速度。

市场机会:

由于技术创新、人口趋势和不断发展的医疗保健实践,尿路上皮癌诊断市场呈现出巨大的成长机会。人工智慧驱动的诊断工具和远端监控等数位健康技术的整合将提高诊断的准确性和可及性。此外,扩大对新型生物标记和基因图谱的研究为诊断进展提供了新途径。策略合作伙伴关係、对创新研究的投资以及开发具有成本效益的诊断解决方案对于利用新机会和维持市场领先地位至关重要。

本报告解决的关键问题

  • 推动全球尿路上皮癌诊断市场成长的关键因素是什么?
  • 哪些诊断技术和方法引领市场?
  • 科技进步如何改变尿路上皮癌诊断市场的竞争格局?
  • 谁是尿路上皮癌诊断市场的主要参与者?
  • 全球尿路上皮癌诊断市场的新趋势和未来前景是什么?

目录

第1章 摘要整理

第2章 市场概要

  • 市场范围/分类
  • 市场定义/范围/限制
  • 蕴藏事项·除外事项

第3章 主要市场趋势

  • 影响市场的主要趋势
  • 产品革新/开发趋势

第4章 主要成功因素

  • 产品的招聘/使用情形分析
  • 产品的USP/特征
  • 最近产品认证与发售
  • 大环境分析
  • 波特分析
  • 法规Scenario
  • 价值链分析

第5章 市场背景

  • 宏观经济要素
  • 预测要素 - 相关性及影响
  • 动态

第6章 COVID-19危机 - 影响评估

  • COVID-19及影响分析
    • 各产品
    • 检查别
    • 各终端用户
    • 各地区
  • 2023年的市场Scenario

第7章 全球市场的需求(金额或规模,一百万美元)分析

  • 过去的市场金额(一百万美元)分析,2019年~2023年
  • 现在及未来市场金额(一百万美元)预测,2024年~2033年
    • 前一年同期比较成长趋势分析
    • 绝对额的机会分析

第8章 全球市场分析:各产品

  • 简介/主要调查结果
  • 过去的市场规模(一百万美元)的分析,各产品,2019年~2023年
  • 现在及未来市场规模(一百万美元)分析与预测,各产品,2024年~2033年
    • 试剂·套件
    • 设备
  • 市场魅力分析:各产品

第9章 全球市场分析:检查别

  • 简介/主要调查结果
  • 过去的市场规模(一百万美元)的分析,检查别,2019年~2023年
  • 现在及未来市场规模(一百万美元)的分析与预测,检查别,2024年~2033年
    • 尿液检查
    • 分子诊断检验
    • 生物标记检验
    • 影像检查
    • 细胞检验
    • 输尿管镜检验
  • 市场魅力分析:检查别

第10章 全球市场分析:各终端用户

  • 简介/主要调查结果
  • 过去的市场规模(一百万美元)的分析,各终端用户,2019~2023年
  • 现在及未来市场规模(一百万美元)的分析与预测,各终端用户,2024年~2033年
    • 医院
    • 诊断检验室
    • 研究·学术机构
    • 临床研究机关
  • 市场魅力分析:各终端用户

第11章 全球市场分析:各地区

  • 简介
  • 过去的市场规模(一百万美元)的分析,各地区,2019~2023年
  • 现在及未来市场规模(一百万美元)的分析与预测,各地区,2024年~2033年
    • 北美
    • 南美
    • 欧洲
    • 南亚
    • 东亚
    • 大洋洲
    • 中东·非洲(MEA)
  • 市场魅力分析:各地区

第12章 北美市场分析

第13章 南美市场分析

第14章 欧洲市场分析

第15章 南亚市场分析

第16章 东亚市场分析

第17章 大洋洲市场分析

第18章 中东·非洲市场分析

第19章 市场结构分析

  • 市场分析:企业各层级
  • 主要企业的市场占有率分析
  • 市场影响分析

第20章 竞争分析

  • 竞争仪表板
  • 品牌和推销策略
  • 主要开发分析
  • 竞争的详细资讯
    • GE Healthcare
    • Roche Holding
    • Illumina
    • IDL Biotech
    • Agilent Technologies
    • Olympus Corporation
    • Philips Healthcare
    • Abbott Molecular
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.(Qiagen NV)
    • Danaher Corporation(Cepheid)

第21章 所使用的前提条件与缩写

第22章 调查手法

简介目录
Product Code: PMRREP14128

Persistence Market Research has recently released a comprehensive report on the worldwide market for urothelial carcinoma diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Urothelial Carcinoma Diagnostics Market Size (2024E): USD 1,808.6 Million
  • Projected Market Value (2033F): USD 4,367.2 Million
  • Global Market Growth Rate (CAGR 2024 to 2033): 10.3%

Urothelial Carcinoma Diagnostics Market - Report Scope:

Urothelial carcinoma diagnostics encompass a range of techniques and tools used to detect and monitor urothelial carcinoma, a type of cancer originating in the bladder and other parts of the urinary system. These diagnostics include imaging techniques, biomarker tests, and molecular diagnostics. The market serves various healthcare settings such as hospitals, diagnostic laboratories, and oncology centers. Market growth is driven by rising incidence of urothelial carcinoma, advancements in diagnostic technologies, and increasing awareness of early cancer detection.

Market Growth Drivers:

The global urothelial carcinoma diagnostics market is propelled by several key factors, including the increasing prevalence of urothelial carcinoma and the growing geriatric population, which is more susceptible to this type of cancer. Advancements in diagnostic technologies, such as the development of next-generation sequencing and liquid biopsy, offer more precise and early detection of cancer, enhancing treatment outcomes. Additionally, the rising adoption of personalized medicine and targeted therapies fuels demand for advanced diagnostic solutions. Increasing healthcare expenditure and improved healthcare infrastructure also contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the urothelial carcinoma diagnostics market faces challenges related to high diagnostic costs and limited access to advanced diagnostic technologies in low-income regions. The complexity of diagnostic procedures and the need for specialized equipment can be barriers to market growth, particularly in emerging markets with constrained healthcare budgets. Additionally, regulatory hurdles and the need for substantial investment in R&D may affect the speed of market entry for new technologies.

Market Opportunities:

The urothelial carcinoma diagnostics market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare practices. The integration of digital health technologies, such as AI-driven diagnostic tools and remote monitoring, enhances diagnostic accuracy and accessibility. Furthermore, the expansion of research into novel biomarkers and genetic profiling offers new avenues for diagnostic advancements. Strategic partnerships, investment in innovative research, and the development of cost-effective diagnostic solutions are crucial to capitalize on emerging opportunities and maintain market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the urothelial carcinoma diagnostics market globally?
  • Which diagnostic technologies and techniques are leading the market, and how are they utilized across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the urothelial carcinoma diagnostics market?
  • Who are the key players contributing to the urothelial carcinoma diagnostics market, and what strategies are they employing to sustain their market positions?
  • What are the emerging trends and future prospects in the global urothelial carcinoma diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urothelial carcinoma diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic solutions, including molecular diagnostics, imaging techniques, and biomarker assays. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Emphasis on clinical research, evidence-based diagnostics, and patient education further supports market growth and enhances diagnostic accuracy.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Becton, Dickinson and Company
  • Siemens Healthineers
  • Bio-Rad Laboratories
  • QIAGEN N.V.
  • Illumina, Inc.
  • Agilent Technologies
  • Sysmex Corporation

Key Segments Covered in Urothelial Carcinoma Diagnostics Industry Research

Product:

  • Reagent and Kits
  • Instruments

Test:

  • Urinalysis Test
  • Molecular Diagnostic Test
  • Biomarker Test
  • maging Test
  • Cytoscopy
  • Ureteroscopy

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Research and Academic Institutes
  • Clinical Research Organizations

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Recent Product Approval and Launches
  • 4.4. PESTLE Analysis
  • 4.5. Porter's Analysis
  • 4.6. Regulatory Scenario
  • 4.7. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Clinical Diagnostics Market Outlook
  • 5.2. Forecast Factors - Relevance and Impact
    • 5.2.1. Technological Advancements
    • 5.2.2. Mergers and Acquisitions
    • 5.2.3. Key Players Historical Growth
    • 5.2.4. Market Consolidation Activities
    • 5.2.5. Availability of Urothelial Carcinoma Diagnostics across Regions
    • 5.2.6. Cost of Product and Services
    • 5.2.7. Product Adoption
  • 5.3. Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Product
    • 6.1.2. By Test
    • 6.1.3. By End User
    • 6.1.4. By Region
  • 6.2. 2023 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2024-2033
    • 8.3.1. Reagent and Kits
    • 8.3.2. Instruments
  • 8.4. Market Attractiveness Analysis By Product

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Test

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Test, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Test, 2024-2033
    • 9.3.1. Urinalysis Test
    • 9.3.2. Molecular Diagnostic Test
    • 9.3.3. Biomarker Test
      • 9.3.3.1. Immuno-Histochemical Assay Test
      • 9.3.3.2. In Situ Hybridization Test
      • 9.3.3.3. Biopsy
      • 9.3.3.4. Cell-Based Test
    • 9.3.4. Imaging Test
    • 9.3.5. Cytoscopy
    • 9.3.6. Ureteroscopy
  • 9.4. Market Attractiveness Analysis By Test

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, by End User

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2033
    • 10.3.1. Hospitals
    • 10.3.2. Diagnostic Laboratories
    • 10.3.3. Research and Academic Institutes
    • 10.3.4. Clinical Research Organizations
  • 10.4. Market Attractiveness Analysis By End User

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2033
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. South Asia
    • 11.3.5. East Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Product
    • 12.3.3. By Test
    • 12.3.4. By End User
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Product
    • 12.4.3. By Test
    • 12.4.4. By End User
  • 12.5. Country Level Analysis and Forecast
    • 12.5.1. U.S. Market Analysis
      • 12.5.1.1. Introduction
      • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.1.2.1. By Product
        • 12.5.1.2.2. By Test
        • 12.5.1.2.3. By End User
    • 12.5.2. Canada Market Analysis
      • 12.5.2.1. Introduction
      • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.2.2.1. By Product
        • 12.5.2.2.2. By Test
        • 12.5.2.2.3. By End User
  • 12.6. Market Trends
  • 12.7. Key Market Participants - Intensity Mapping
  • 12.8. Drivers and Restraints - Impact Analysis

13. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Mexico
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Test
    • 13.3.3. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Test
    • 13.4.4. By End User
  • 13.5. Country Level Analysis and Forecast
    • 13.5.1. Brazil Market Analysis
      • 13.5.1.1. Introduction
      • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.1.2.1. By Product
        • 13.5.1.2.2. By Test
        • 13.5.1.2.3. By End User
    • 13.5.2. Mexico Market Analysis
      • 13.5.2.1. Introduction
      • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.2.2.1. By Product
        • 13.5.2.2.2. By Test
        • 13.5.2.2.3. By End User
    • 13.5.3. Argentina Market Analysis
      • 13.5.3.1. Introduction
      • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.3.2.1. By Product
        • 13.5.3.2.2. By Test
        • 13.5.3.2.3. By End User
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. France
      • 14.3.1.3. Italy
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. Russia
      • 14.3.1.7. BENELUX
      • 14.3.1.8. Nordic Countries
      • 14.3.1.9. Rest of Europe
    • 14.3.2. By Product
    • 14.3.3. By Test
    • 14.3.4. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Test
    • 14.4.4. By End User
  • 14.5. Country Level Analysis and Forecast
    • 14.5.1. Germany Market Analysis
      • 14.5.1.1. Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Product
        • 14.5.1.2.2. By Test
        • 14.5.1.2.3. By End User
    • 14.5.2. France Market Analysis
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Product
        • 14.5.2.2.2. By Test
        • 14.5.2.2.3. By End User
    • 14.5.3. Italy Market Analysis
      • 14.5.3.1. Introduction
      • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.3.2.1. By Product
        • 14.5.3.2.2. By Test
        • 14.5.3.2.3. By End User
    • 14.5.4. U.K. Market Analysis
      • 14.5.4.1. Introduction
      • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.4.2.1. By Product
        • 14.5.4.2.2. By Test
        • 14.5.4.2.3. By End User
    • 14.5.5. Spain Market Analysis
      • 14.5.5.1. Introduction
      • 14.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.5.2.1. By Product
        • 14.5.5.2.2. By Test
        • 14.5.5.2.3. By End User
    • 14.5.6. Russia Market Analysis
      • 14.5.6.1. Introduction
      • 14.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.6.2.1. By Product
        • 14.5.6.2.2. By Test
        • 14.5.6.2.3. By End User
    • 14.5.7. Nordic Countries Market Analysis
      • 14.5.7.1. Introduction
      • 14.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.7.2.1. By Product
        • 14.5.7.2.2. By Test
        • 14.5.7.2.3. By End User
    • 14.5.8. BENELUX Market Analysis
      • 14.5.8.1. Introduction
      • 14.5.8.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.8.2.1. By Product
        • 14.5.8.2.2. By Test
        • 14.5.8.2.3. By End User
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Thailand
      • 15.3.1.3. Indonesia
      • 15.3.1.4. Malaysia
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Product
    • 15.3.3. By Test
    • 15.3.4. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Test
    • 15.4.4. By End User
  • 15.5. Country Level Analysis and Forecast
    • 15.5.1. India Market Analysis
      • 15.5.1.1. Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Product
        • 15.5.1.2.2. By Test
        • 15.5.1.2.3. By End User
    • 15.5.2. Thailand Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Product
        • 15.5.2.2.2. By Test
        • 15.5.2.2.3. By End User
    • 15.5.3. Indonesia Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Product
        • 15.5.3.2.2. By Test
        • 15.5.3.2.3. By End User
    • 15.5.4. Malaysia Market Analysis
      • 15.5.4.1. Introduction
      • 15.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.4.2.1. By Product
        • 15.5.4.2.2. By Test
        • 15.5.4.2.3. By End User
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Product
    • 16.3.3. By Test
    • 16.3.4. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Test
    • 16.4.4. By End User
  • 16.5. Country Level Analysis and Forecast
    • 16.5.1. China Market Analysis
      • 16.5.1.1. Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Product
        • 16.5.1.2.2. By Test
        • 16.5.1.2.3. By End User
    • 16.5.2. Japan Market Analysis
      • 16.5.2.1. Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Product
        • 16.5.2.2.2. By Test
        • 16.5.2.2.3. By End User
    • 16.5.3. South Korea Market Analysis
      • 16.5.3.1. Introduction
      • 16.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.3.2.1. By Product
        • 16.5.3.2.2. By Test
        • 16.5.3.2.3. By End User
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. Oceania Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Product
    • 17.3.3. By Test
    • 17.3.4. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Test
    • 17.4.4. By End User
  • 17.5. Country Level Analysis and Forecast
    • 17.5.1. Australia Market Analysis
      • 17.5.1.1. Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Product
        • 17.5.1.2.2. By Test
        • 17.5.1.2.3. By End User
    • 17.5.2. New Zealand Market Analysis
      • 17.5.2.1. Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Product
        • 17.5.2.2.2. By Test
        • 17.5.2.2.3. By End User
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkiye
      • 18.3.1.3. Northern Africa
      • 18.3.1.4. South Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Product
    • 18.3.3. By Test
    • 18.3.4. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By Test
    • 18.4.4. By End User
  • 18.5. Country Level Analysis and Forecast
    • 18.5.1. GCC Countries Market Analysis
      • 18.5.1.1. Introduction
      • 18.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.1.2.1. By Product
        • 18.5.1.2.2. By Test
        • 18.5.1.2.3. By End User
    • 18.5.2. Turkiye Market Analysis
      • 18.5.2.1. Introduction
      • 18.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.2.2.1. By Product
        • 18.5.2.2.2. By Test
        • 18.5.2.2.3. By End User
    • 18.5.3. Northern Africa Market Analysis
      • 18.5.3.1. Introduction
      • 18.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.3.2.1. By Product
        • 18.5.3.2.2. By Test
        • 18.5.3.2.3. By End User
    • 18.5.4. South Africa Market Analysis
      • 18.5.4.1. Introduction
      • 18.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.4.2.1. By Product
        • 18.5.4.2.2. By Test
        • 18.5.4.2.3. By End User
  • 18.6. Market Trends
  • 18.7. Key Market Participants - Intensity Mapping
  • 18.8. Drivers and Restraints - Impact Analysis

19. Market Structure Analysis

  • 19.1. Market Analysis by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Branding and Promotional Strategies
  • 20.3. Key Development Analysis
  • 20.4. Competition Deep Dive
    • 20.4.1. GE Healthcare
      • 20.4.1.1. Overview
      • 20.4.1.2. Product Portfolio
      • 20.4.1.3. Key Financials
      • 20.4.1.4. SWOT Analysis
      • 20.4.1.5. Sales Footprint
      • 20.4.1.6. Strategy Overview
        • 20.4.1.6.1. Marketing Strategy
        • 20.4.1.6.2. Product Strategy
        • 20.4.1.6.3. Channel Strategy
    • 20.4.2. Roche Holding
      • 20.4.2.1. Overview
      • 20.4.2.2. Product Portfolio
      • 20.4.2.3. Key Financials
      • 20.4.2.4. SWOT Analysis
      • 20.4.2.5. Sales Footprint
      • 20.4.2.6. Strategy Overview
        • 20.4.2.6.1. Marketing Strategy
        • 20.4.2.6.2. Product Strategy
        • 20.4.2.6.3. Channel Strategy
    • 20.4.3. Illumina
      • 20.4.3.1. Overview
      • 20.4.3.2. Product Portfolio
      • 20.4.3.3. Key Financials
      • 20.4.3.4. SWOT Analysis
      • 20.4.3.5. Sales Footprint
      • 20.4.3.6. Strategy Overview
        • 20.4.3.6.1. Marketing Strategy
        • 20.4.3.6.2. Product Strategy
        • 20.4.3.6.3. Channel Strategy
    • 20.4.4. IDL Biotech
      • 20.4.4.1. Overview
      • 20.4.4.2. Product Portfolio
      • 20.4.4.3. Key Financials
      • 20.4.4.4. SWOT Analysis
      • 20.4.4.5. Sales Footprint
      • 20.4.4.6. Strategy Overview
        • 20.4.4.6.1. Marketing Strategy
        • 20.4.4.6.2. Product Strategy
        • 20.4.4.6.3. Channel Strategy
    • 20.4.5. Agilent Technologies
      • 20.4.5.1. Overview
      • 20.4.5.2. Product Portfolio
      • 20.4.5.3. Key Financials
      • 20.4.5.4. SWOT Analysis
      • 20.4.5.5. Sales Footprint
      • 20.4.5.6. Strategy Overview
        • 20.4.5.6.1. Marketing Strategy
        • 20.4.5.6.2. Product Strategy
        • 20.4.5.6.3. Channel Strategy
    • 20.4.6. Olympus Corporation
      • 20.4.6.1. Overview
      • 20.4.6.2. Product Portfolio
      • 20.4.6.3. Key Financials
      • 20.4.6.4. SWOT Analysis
      • 20.4.6.5. Sales Footprint
      • 20.4.6.6. Strategy Overview
        • 20.4.6.6.1. Marketing Strategy
        • 20.4.6.6.2. Product Strategy
        • 20.4.6.6.3. Channel Strategy
    • 20.4.7. Philips Healthcare
      • 20.4.7.1. Overview
      • 20.4.7.2. Product Portfolio
      • 20.4.7.3. Key Financials
      • 20.4.7.4. SWOT Analysis
      • 20.4.7.5. Sales Footprint
      • 20.4.7.6. Strategy Overview
        • 20.4.7.6.1. Marketing Strategy
        • 20.4.7.6.2. Product Strategy
        • 20.4.7.6.3. Channel Strategy
    • 20.4.8. Abbott Molecular
      • 20.4.8.1. Overview
      • 20.4.8.2. Product Portfolio
      • 20.4.8.3. Key Financials
      • 20.4.8.4. SWOT Analysis
      • 20.4.8.5. Sales Footprint
      • 20.4.8.6. Strategy Overview
        • 20.4.8.6.1. Marketing Strategy
        • 20.4.8.6.2. Product Strategy
        • 20.4.8.6.3. Channel Strategy
    • 20.4.9. Bio-Rad Laboratories, Inc.
      • 20.4.9.1. Overview
      • 20.4.9.2. Product Portfolio
      • 20.4.9.3. Key Financials
      • 20.4.9.4. SWOT Analysis
      • 20.4.9.5. Sales Footprint
      • 20.4.9.6. Strategy Overview
        • 20.4.9.6.1. Marketing Strategy
        • 20.4.9.6.2. Product Strategy
        • 20.4.9.6.3. Channel Strategy
    • 20.4.10. Thermo Fisher Scientific, Inc. (Qiagen N.V.)
      • 20.4.10.1. Overview
      • 20.4.10.2. Product Portfolio
      • 20.4.10.3. Key Financials
      • 20.4.10.4. SWOT Analysis
      • 20.4.10.5. Sales Footprint
      • 20.4.10.6. Strategy Overview
        • 20.4.10.6.1. Marketing Strategy
        • 20.4.10.6.2. Product Strategy
        • 20.4.10.6.3. Channel Strategy
    • 20.4.11. Danaher Corporation (Cepheid)
      • 20.4.11.1. Overview
      • 20.4.11.2. Product Portfolio
      • 20.4.11.3. Key Financials
      • 20.4.11.4. SWOT Analysis
      • 20.4.11.5. Sales Footprint
      • 20.4.11.6. Strategy Overview
        • 20.4.11.6.1. Marketing Strategy
        • 20.4.11.6.2. Product Strategy
        • 20.4.11.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology